Dashboard
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 21.93
Poor long term growth as Operating profit has grown by an annual rate -19.80% of over the last 5 years
With ROE of 5.71%, it has a very attractive valuation with a 1.39 Price to Book Value
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,498,202 Million (Large Cap)
24.00
NA
0.01%
-0.06
6.26%
1.81
Total Returns (Price + Dividend) 
Eisai Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Eisai Co. Stock Hits Day Low at JPY 4,429 Amid Price Pressure
Eisai Co., Ltd. faced a notable decline in stock performance on October 14, 2025, amid ongoing market challenges. The company has seen a significant decrease over the past week and month, with troubling long-term performance indicators, including a substantial drop in operating profit and a negative debt-equity ratio.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Foreign Institutions
Held in 0 Schemes (0%)
Held by 3 Foreign Institutions (0.09%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 7.66% vs -12.91% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 2,430.86% vs -97.52% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 6.42% vs -0.36% in Mar 2024
YoY Growth in year ended Mar 2025 is 9.76% vs -22.96% in Mar 2024






